BlueCross BlueShield
Federal Employee Program
Federal Employee Program®
1310 G Street, N.W.
Washington, D.C. 20005
202.942.1000
Fax 202.942.1125

# 5.90.54

| | | | |
|---|---|---|---|
| **Section:** | Prescription Drugs | **Effective Date:** | July 1, 2022 |
| **Subsection:** | Topical Products | **Original Policy Date:** | March 25, 2022 |
| **Subject:** | Vuity | **Page:** | 1 of 4 |

***Last Review Date:*** June 16, 2022

# Vuity

## Description

### Vuity (pilocarpine hydrochloride ophthalmic solution)

**Background**
Presbyopia is an age-related condition that reduces the eye's ability to focus on nearby objects. As people age, the lens in the eye becomes less flexible and able accommodate changes in focus needed to visualize objects up close. Pilocarpine (the active ingredient in Vuity) stimulates smooth muscle, through muscarinic receptors, to promote contraction of the iris sphincter muscles and thereby constricting the pupil to improve near and intermediate vision (1).

**Regulatory Status**
FDA-approved indication: Vuity is indicated for the treatment of presbyopia in adults (1).

Patients using Vuity should be advised that the medication can decrease the ability to see at night or in low light situations. Patient should be advised to exercise caution at night and avoid driving or using machinery if vision is not clear (1).

Retinal detachment has been reported with the use of other miotic agents. Susceptible individuals and those with pre-existing retinal disease should be advised to seek immediate medical care with sudden onset of vision loss (1).

Vuity is not recommended in patients where iritis is present as adhesions (synechiae) may form between the iris and lens (1).

Contact lens wearers should be advised to remove their lenses prior to instillation of Vuity and to wait 10 minutes after dosing before reinserting contact lenses (1).

Presbyopia does not occur in pediatric population (1).

**Related policies**

## Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Vuity may be considered **medically necessary** for the treatment of presbyopia and if the conditions indicated below are met.

Vuity may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 40 through 55 years of age

**Diagnosis**

Patient must have the following:

Presbyopia

**AND ALL** of the following:

1. Corrective eyeglasses or contact lenses have not been able to resolve the presbyopia symptoms **OR** patient is intolerant or contraindicated to corrective eyeglasses or contact lenses
2. Prescribed by or recommended by an optometrist or ophthalmologist
3. Prescriber agrees to advise the patient to administer Vuity in the morning
4. Dose will not exceed 1 drop per eye per day
5. **NO** glaucoma or ocular hypertension
6. **NO** dual therapy with any other ophthalmic pilocarpine formulation

## Prior–Approval *Renewal* Requirements

**Age** 40 years of age or older

**Diagnosis**

Patient must have the following:

Presbyopia

**AND ALL** of the following:

1. Patient has demonstrated improvement from baseline presbyopia by **ALL** of the following:
   a. Gained 3 lines or more in mesopic, high contrast, binocular distance corrected near visual acuity (DCNVA)
   b. Did **NOT** lose more than 1 line (5 letters) of corrected distance visual acuity CDVA) with the same refractive correction since starting treatment
2. Prescriber agrees to advise the patient to administer Vuity in the morning
3. Dose will not exceed 1 drop per eye per day
4. **NO** glaucoma or ocular hypertension
5. **NO** dual therapy with any other ophthalmic pilocarpine formulation

## Policy Guidelines

### Pre–PA Allowance

None

### Prior–Approval Limits

**Quantity** 5 bottles (2.5 mL / bottle) per 90 days

**Duration** 6 months

### Prior–Approval *Renewal* Limits

**Quantity** 5 bottles (2.5 mL / bottle) per 90 days

**Duration** 12 months

## Rationale

**Summary**
Vuity is a parasympathetic stimulating agent that can help overcome age-related loss of near distance visual acuity through contraction of the iris sphincter muscles. This leads to pupillary contraction and an improvement in near and moderate distance vision. Vuity decreases the ability of the pupil to dilate in low light situations and patients should be warned of operating heavy machinery or driving in low-light conditions or when vision is not clear. Contact wearers should be advised to separate instillation of Vuity and insertion or re-insertion of contact lenses by 10 minutes. Retinal detachment has been reported with other miotics and patients should seek immediate medical care if sudden vision loss occurs. Presbyopia does not occur in pediatric population (1).

Prior approval is required to ensure the safe, clinically appropriate and cost effective use of Vuity while maintaining optimal therapeutic outcomes.

**References**

1. Vuity [package insert]. North Chicago, IL: Allergan, an AbbVie Company; October 2021.

## Policy History

| Date | Action |
|---|---|
| March 2022 | Addition to PA |
| June 2022 | Annual review |

## Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 16, 2022 and is effective on July 1, 2022.**